Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

[1]  A. Keogh,et al.  Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. , 2003, British journal of clinical pharmacology.

[2]  David Colquhoun,et al.  Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up , 2002, The Lancet.

[3]  Z. Kmietowicz.  Statins are the new aspirin, Oxford researchers say , 2001, BMJ : British Medical Journal.

[4]  S. Gottlieb,et al.  US consumer groups allege misleading drug claims , 2001, BMJ : British Medical Journal.

[5]  F. Charatan.  Exercise and diet reduce risk of diabetes, US study shows , 2001, BMJ : British Medical Journal.

[6]  F. Charatan.  Bayer decides to withdraw cholesterol lowering drug , 2001, BMJ : British Medical Journal.

[7]  F. Charatan.  Foreigners flock to Cuba for medical care , 2001, BMJ : British Medical Journal.

[8]  F. Charatan.  US spending on prescription drugs rose by 19% in 2000 , 2001, BMJ : British Medical Journal.

[9]  A. Peyer,et al.  HMG‐CoA reductase inhibitors and P‐glycoprotein modulation , 2001, British journal of pharmacology.

[10]  L. Wallentin,et al.  Early statin treatment following acute myocardial infarction and 1-year survival. , 2001, JAMA.

[11]  A. Berger,et al.  The renaissance of C reactive protein , 2001, BMJ : British Medical Journal.

[12]  C. Dessy,et al.  Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance , 2001, Circulation.

[13]  G. Lowe,et al.  Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. , 2000, The New England journal of medicine.

[14]  T. Lee,et al.  Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. , 2000, The American journal of cardiology.

[15]  G. Alexandridis,et al.  Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil. , 2000, The American journal of medicine.

[16]  P. Hansten,et al.  Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. , 2000, Archives of internal medicine.

[17]  B. Koçak,et al.  A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report. , 2000, Angiology.

[18]  R. Krause,et al.  Acute rhabdomyolysis after atorvastatin and fusidic acid therapy. , 2000, The American journal of medicine.

[19]  R. Davidson,et al.  Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells , 2000 .

[20]  A. Olsson,et al.  Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia , 2000 .

[21]  S. Cummings,et al.  Do statins prevent both cardiovascular disease and fracture? , 2000, JAMA.

[22]  J. Avorn,et al.  HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. , 2000, JAMA.

[23]  H Jick,et al.  HMG-CoA reductase inhibitors and the risk of fractures. , 2000, JAMA.

[24]  P. Macdonald,et al.  Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[25]  T. Mjörndal,et al.  HMG-CoA Reductase Inhibitors and Myotoxicity , 2000, Drug safety.

[26]  A. Allegra,et al.  Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy , 2000, Clinical pharmacology and therapeutics.

[27]  T. Ishizaki,et al.  Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. , 2000, Pharmacology & therapeutics.

[28]  P. McGettigan,et al.  Growth in use of statins after trials is not targeted to most appropriate patients , 2000, Clinical pharmacology and therapeutics.

[29]  M. B. Bottorf,et al.  Comment: Possible Interaction between Nefazodone and Pravastatin , 2000, The Annals of pharmacotherapy.

[30]  I. U. Haq,et al.  Coronary and cardiovascular risk estimation for primary prevention:validation of a new Sheffield table in the 1995 Scottish health survey population , 2000, BMJ : British Medical Journal.

[31]  R. Jackson,et al.  Updated New Zealand cardiovascular disease risk-benefit prediction guide , 2000, BMJ : British Medical Journal.

[32]  C. Possidente,et al.  Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient. , 2000, The American journal of medicine.

[33]  M. Rieser,et al.  Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[34]  S. Hall,et al.  The interaction of diltiazem with simvastatin , 2000, Clinical pharmacology and therapeutics.

[35]  R. Scalley,et al.  Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil. , 2000, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[36]  M. Linton,et al.  Current perspectives on statins. , 2000, Circulation.

[37]  R. Boyd,et al.  Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion , 2000, Journal of clinical pharmacology.

[38]  V. Sasseville,et al.  A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.

[39]  M. Schubert,et al.  Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin , 1999, Journal of internal medicine.

[40]  R. Herman,et al.  Drug interactions and the statins. , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[41]  J. Cheigh,et al.  Rhabdomyolysis Associated with Concomitant Use of Atorvastatin and Cyclosporine , 1999, The Annals of pharmacotherapy.

[42]  L. Ramsay,et al.  Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. , 1999, British journal of clinical pharmacology.

[43]  M. Mercuri,et al.  Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. , 1999, The American journal of cardiology.

[44]  Jamie J. Zhao,et al.  Grapefruit juice has minimal effects on plasma concentrations of lovastatin‐derived 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors , 1999, Clinical pharmacology and therapeutics.

[45]  P. Weissberg,et al.  Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. , 1999, Atherosclerosis.

[46]  M. Bottorff.  'Fire and forget?' - pharmacological considerations in coronary care. , 1999, Atherosclerosis.

[47]  W. Aengevaeren.  Beyond lipids - the role of the endothelium in coronary artery disease. , 1999, Atherosclerosis.

[48]  H. Arntz.  Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events. , 1999, Atherosclerosis.

[49]  Y. Lampl,et al.  Rhabdomyolysis induced by simvastatin and ketoconazole treatment. , 1999, Clinical neuropharmacology.

[50]  A. Castro‐Beiras,et al.  Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine. , 1999, Transplantation proceedings.

[51]  A. Mazzu,et al.  Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers. , 1999, Clinical therapeutics.

[52]  T. Lehtimäki,et al.  Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study , 1999, BMJ.

[53]  M. Moghadasian.  Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. , 1999, Life Science.

[54]  R. Knopp.  Drug treatment of lipid disorders. , 1999, The New England journal of medicine.

[55]  S. Grundy,et al.  Cholesterol Lowering in the Elderly Population , 1999 .

[56]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[57]  P. Neuvonen,et al.  Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin , 1999, Clinical pharmacology and therapeutics.

[58]  K. Berg,et al.  Interaction between lovastatin and cyclosporine A after heart and kidney transplantation. , 1999, Transplantation proceedings.

[59]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[60]  L L Leape,et al.  Reducing errors in medicine , 1999, Quality in health care : QHC.

[61]  C. Alderman.  Possible Interaction between Nefazodone and Pravastatin , 1999, The Annals of pharmacotherapy.

[62]  K. Lake,et al.  Effect of Short-Term Rifampin on Stable Cyclosporine Concentrations , 1999, The Annals of pharmacotherapy.

[63]  M. Dominiczak,et al.  Efficacy of statin therapy: possible effect of phenytoin , 1999, Postgraduate medical journal.

[64]  D. Capone,et al.  Effects of Simvastatin and Pravastatin on Hyperlipidemia and Cyclosporin Blood Levels in Renal Transplant Recipients , 1999, American Journal of Nephrology.

[65]  M. Dobrinska,et al.  Calcium channel blocker-simvastatin interaction. , 1999, Clinical pharmacology and therapeutics.

[66]  S. Olson,et al.  Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations , 1999, Journal of clinical pharmacology.

[67]  A. Allegra,et al.  Pro-apoptotic effect of fluvastatin on human smooth muscle cells. , 1999, European journal of pharmacology.

[68]  A. Serajuddin,et al.  DIFFERENTIATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A REDUCTASE INHIBITORS BY THEIR RELATIVE LIPOPHILICITY , 1999 .

[69]  A. Markham,et al.  Fluvastatin: a review of its use in lipid disorders. , 1999, Drugs.

[70]  L. Kindred,et al.  Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy. , 1999, The American journal of cardiology.

[71]  C. Funck-Brentano,et al.  Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics , 1999, Fundamental & clinical pharmacology.

[72]  Mark M. Roden,et al.  Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.

[73]  V. Fischer,et al.  The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[74]  B. Ma,et al.  Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. , 1999, British journal of clinical pharmacology.

[75]  C. Oo,et al.  Effect of Orlistat, a Novel Anti-Obesity Agent, on the Pharmacokinetics and Pharmacodynamics of Pravastatin in Patients with Mild Hypercholesterolaemia , 1999 .

[76]  L Fritsche,et al.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[77]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[78]  U. Christians,et al.  Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[79]  P. Neuvonen,et al.  Grapefruit juice increases serum simvastatin and atorvastatin but not pravastatin , 1999 .

[80]  Jennifer C. Lin,et al.  The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin , 1999, Journal of clinical pharmacology.

[81]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[82]  H. Bays,et al.  Drug Interactions of Lipid-Altering Drugs , 1998, Drug safety.

[83]  G. Mancia,et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. , 1998, Atherosclerosis.

[84]  P. Neuvonen,et al.  Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.

[85]  J. M. Malinowski.  Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[86]  U. Christians,et al.  Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? , 1998, Pharmacology & therapeutics.

[87]  S. Hall,et al.  The interaction of diltiazem with lovastatin and pravastatin , 1998, Clinical pharmacology and therapeutics.

[88]  H. Bischoff,et al.  Preclinical and clinical pharmacology of cerivastatin. , 1998, The American journal of cardiology.

[89]  S. Olson,et al.  Atorvastatin does not Produce a Clinically Significant Effect on the Pharmacokinetics of Terfenadine , 1998, Journal of clinical pharmacology.

[90]  P. Neuvonen,et al.  Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapeutics.

[91]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[92]  P. Neuvonen,et al.  Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. , 1998, British journal of clinical pharmacology.

[93]  W. Haefeli,et al.  Rhabdomyolysis due to interaction of simvastatin with mibefradil , 1998, The Lancet.

[94]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[95]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[96]  P. Neuvonen,et al.  Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.

[97]  J. Alsenz,et al.  Active Apical Secretory Efflux of the HIV Protease Inhibitors Saquinavir and Ritonavir in Caco-2 Cell Monolayers , 1998, Pharmaceutical Research.

[98]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[99]  Nicholas Christenfeld,et al.  Increase in US medication-error deaths between 1983 and 1993 , 1998, The Lancet.

[100]  K. Ochmann,et al.  PHARMACOKINETICS AND DISPOSITION , 1998 .

[101]  D. Illingworth,et al.  Rhabdomyolysis after taking atorvastatin with gemfibrozil. , 1998, The American journal of cardiology.

[102]  O. Faergeman,et al.  Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.

[103]  M. Maioli,et al.  Reduction of Albumin Excretion Rate in Normotensive Microalbuminuric Type 2 Diabetic Patients During Long-Term Simvastatin Treatment , 1997, Diabetes Care.

[104]  J. Seeger,et al.  Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors , 1997, Pharmacotherapy.

[105]  G. Kyriakides,et al.  Fluvastatin in renal transplantation. , 1997, Transplantation proceedings.

[106]  R. Stern,et al.  Atorvastatin Does Not Alter the Anticoagulant Activity of Warfarin , 1997, Journal of clinical pharmacology.

[107]  U. Christians,et al.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.

[108]  S. Olson,et al.  Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin , 1997, Journal of clinical pharmacology.

[109]  R. Weintraub,et al.  Drug Interactions with Grapefruit Juice , 1997, Clinical pharmacokinetics.

[110]  A. Gotto,et al.  Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). , 1997, The American journal of cardiology.

[111]  C. Hennekens,et al.  Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. , 1997, JAMA.

[112]  M. Eriksson,et al.  Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? , 1997, The Lancet.

[113]  J. Grunden,et al.  Lovastatin-Induced Rhabdomyolysis Possibly Associated with Clarithromycin and Azithromycin , 1997, The Annals of pharmacotherapy.

[114]  K. Ochmann,et al.  Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. , 1997, International journal of clinical pharmacology and therapeutics.

[115]  C. Harrell,et al.  Potential Warfarin—Fluvastatin Interaction , 1997, The Annals of pharmacotherapy.

[116]  A. Mazzu,et al.  111 Pharmacokinetics of cerivastatin administration with and without food in the morning and evening , 1997 .

[117]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[118]  A. Mazzu,et al.  109 Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin , 1997 .

[119]  J. Kuhlmann,et al.  Influence of cholestyramine on the pharmacokinetics of cerivastatin. , 1997, International journal of clinical pharmacology and therapeutics.

[120]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[121]  D. McTavish,et al.  Atorvastatin , 2012, Drugs.

[122]  M. Southworth,et al.  The Use of HMG-CoA Reductase Inhibitors to Prevent Accelerated Graft Atherosclerosis in Heart Transplant Patients , 1997, The Annals of pharmacotherapy.

[123]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[124]  B. Kasiske,et al.  Hyperlipidemia in solid organ transplantation. , 1997, Transplantation.

[125]  D. McTavish,et al.  Pravastatin , 2012, Drugs.

[126]  C. Glueck,et al.  Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. , 1997, JAMA.

[127]  David W. Bates,et al.  The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group , 1997 .

[128]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[129]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[130]  S. Aspinall,et al.  Potential Interaction between Warfarin and Fluvastatin , 1996, The Annals of pharmacotherapy.

[131]  E. V. van Puijenbroek,et al.  Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil , 1996, Journal of internal medicine.

[132]  Y. Horsmans,et al.  Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors , 1996, Clinical pharmacokinetics.

[133]  B. Buckley,et al.  Statins do more than just lower cholesterol , 1996, The Lancet.

[134]  G. Thorgeirsson,et al.  Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. , 1996, Archives of internal medicine.

[135]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[136]  M. Horn.  Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. , 1996, Archives of dermatology.

[137]  K. Matsuyama,et al.  Drug interaction between simvastatin and cholestyramine in vitro and in vivo. , 1996, Biological & pharmaceutical bulletin.

[138]  I. Vandewiele,et al.  Drug-interaction-induced rhabdomyolysis. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[139]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[140]  W. Hollingworth,et al.  Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population , 1996, BMJ.

[141]  G. Thorgeirsson,et al.  Cholesterol lowering and the use of healthcare resources. Results of the Scandinavian Simvastatin Survival Study. , 1996, Circulation.

[142]  S. Gardner,et al.  Combination Therapy with Low‐Dose Lovastatin and Niacin Is as Effective as Higher‐Dose Lovastatin , 1996, Pharmacotherapy.

[143]  R. Benton,et al.  Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram , 1996, Clinical pharmacology and therapeutics.

[144]  A. Sedman,et al.  Effects of Atorvastatin, an HMG‐CoA Reductase Inhibitor, on Hepatic Oxidative Metabolism of Antipyrine , 1996, Journal of clinical pharmacology.

[145]  D. Hunninghake,et al.  Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial , 1996, Journal of cardiovascular pharmacology and therapeutics.

[146]  G. Plosker,et al.  Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. , 1996, Drugs.

[147]  E. Grau,et al.  Simvastatin-oral anticoagulant interaction , 1996, The Lancet.

[148]  D. Waters,et al.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. , 1995, Circulation.

[149]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[150]  A. Wang,et al.  Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. , 1995, Transplantation.

[151]  J. A. Johnson,et al.  Drug-Related Morbidity and Mortality: A Cost-of-Illness Model , 1995 .

[152]  T. Leemann,et al.  In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)‐fluvastatin , 1995, Clinical pharmacology and therapeutics.

[153]  P. Glue,et al.  Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine , 1995, Clinical pharmacology and therapeutics.

[154]  A. Sedman,et al.  Effect of Food on the Bioavailability of Atorvastatin, an HMG‐CoA Reductase Inhibitor , 1995, Journal of clinical pharmacology.

[155]  B. Rosner,et al.  The influence of pretreatment lew density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials , 1995 .

[156]  L. Yeatman,et al.  Effect of pravastatin on outcomes after cardiac transplantation. , 1995, The New England journal of medicine.

[157]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[158]  R. Dupuis,et al.  Approaches to The Treatment of Hyperlipidemia in the Solid Organ Transplant Recipient , 1995, The Annals of pharmacotherapy.

[159]  W. Garnett.  Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[160]  D. Adam,et al.  Macrolide Antibacterials , 1995, Drug safety.

[161]  J. Vacek,et al.  Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. , 1995, The American journal of cardiology.

[162]  R. Goldberg,et al.  A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. , 1995, The American journal of cardiology.

[163]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[164]  S. Krähenbühl,et al.  Interaction between grapefruit juice and midazolam in humans , 1995, Clinical pharmacology and therapeutics.

[165]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[166]  A. Wang,et al.  The interaction of fluvastatin and cyclosporin A in renal transplant patients. , 1995, International journal of clinical pharmacology and therapeutics.

[167]  L. Howes,et al.  Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. , 1995, The American journal of cardiology.

[168]  C. Furberg,et al.  Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) , 1995, The American journal of cardiology.

[169]  R. Schall,et al.  No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and Warfarin , 1995, Journal of clinical pharmacology.

[170]  W. Weintraub,et al.  Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. , 1995, The New England journal of medicine.

[171]  G. Davı̀,et al.  Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[172]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[173]  A. Kandus,et al.  Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression. , 1994, Transplantation proceedings.

[174]  R. S. Rosenson,et al.  Safety of combined pravastatin-gemfibrozil therapy. , 1994, The American journal of cardiology.

[175]  J. Quion,et al.  Clinical Pharmacokinetics of Pravastatin , 1994, Clinical pharmacokinetics.

[176]  L. Amorosa,et al.  Fluvastatin with and without niacin for hypercholesterolemia. , 1994, The American journal of cardiology.

[177]  M. Sugimachi,et al.  Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. , 1994, Circulation.

[178]  C. Blum,et al.  Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1994, The American journal of cardiology.

[179]  L. Jokubaitis.  Updated clinical safety experience with fluvastatin. , 1994, The American journal of cardiology.

[180]  J. Deslypere.  Clinical implications of the biopharmaceutical properties of fluvastatin. , 1994, The American journal of cardiology.

[181]  T. Thalhammer,et al.  Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver. , 1994, Anticancer research.

[182]  A. Troendle,et al.  Pharmacokinetics of fluvastatin and specific drug interactions. , 1993, American journal of hypertension.

[183]  M. Ducharme,et al.  Trough concentrations of cyclosporine in blood following administration with grapefruit juice. , 1993, British journal of clinical pharmacology.

[184]  H. Abboud,et al.  Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. , 1993, Kidney international.

[185]  A. Gavazzi,et al.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.

[186]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[187]  D. Bailey,et al.  Grapefruit juice–felodipine interaction: Mechanism, predictability, and effect of naringin , 1993, Clinical pharmacology and therapeutics.

[188]  H. Pan,et al.  Effect of food on pravastatin pharmacokinetics and pharmacodynamics. , 1993, International journal of clinical pharmacology, therapy and toxicology.

[189]  T. Ishikawa,et al.  Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. , 1993, Gastroenterology.

[190]  Colleen A. Colley,et al.  Polypharmacy , 1993, Journal of General Internal Medicine.

[191]  A. Fujimura,et al.  Influence of lacidipine on plasma aldosterone production in hypertensive subjects , 1993 .

[192]  K. Widhalm,et al.  Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A. , 1992, Transplantation proceedings.

[193]  T R Miller,et al.  Principles of therapeutics. , 1992, The Veterinary clinics of North America. Equine practice.

[194]  F. Tse,et al.  Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.

[195]  S. Schneider,et al.  Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits. , 1992, Japanese heart journal.

[196]  B. A. Mueller,et al.  Lovastatin-Induced Rhabdomyolysis in the Absence of Concomitant Drugs , 1992, The Annals of pharmacotherapy.

[197]  H. Pan,et al.  Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment , 1992, Journal of clinical pharmacology.

[198]  N. Yoshimura,et al.  THE EFFECTS OF PRAVASTATIN ON HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS1 , 1992, Transplantation.

[199]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[200]  M. Yacoub,et al.  Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. , 1991, International journal of cardiology.

[201]  J. Feely,et al.  Effects of HMG CoA Reductase Inhibitors on Warfarin Binding , 1991 .

[202]  P. Schwandt,et al.  Interaction between fibre and Iovastatin , 1991, The Lancet.

[203]  C. Shear,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. , 1991, The American journal of medicine.

[204]  H. Pan,et al.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. , 1991, British journal of clinical pharmacology.

[205]  R. Tyndale,et al.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). , 1991, British journal of clinical pharmacology.

[206]  L. Stevenson,et al.  Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. , 1990, Circulation.

[207]  S. Ahmad,et al.  Lovastatin. Warfarin interaction. , 1990, Archives of internal medicine.

[208]  K. Goa,et al.  Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. , 1990, Drugs.

[209]  E. Muls,et al.  The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia , 1990, Journal of internal medicine.

[210]  H. Pan,et al.  Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia , 1990, Clinical pharmacology and therapeutics.

[211]  K. Hasegawa,et al.  Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 1990, Biochimica et biophysica acta.

[212]  T. Gross,et al.  Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. , 1990, JAMA.

[213]  R. Hené,et al.  Partial remission of nephrotic syndrome in patient on long-term simvastatin , 1990, The Lancet.

[214]  D. Illingworth,et al.  The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia. , 1990, Metabolism: clinical and experimental.

[215]  I. Chen,et al.  Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[216]  S. Singhvi,et al.  Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. , 1990, British journal of clinical pharmacology.

[217]  I. Chen,et al.  The physiological disposition of lovastatin. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[218]  J. Tobert.  Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.

[219]  C. Fuchs,et al.  Lovastatin and rhabdomyolysis. , 1988, Annals of internal medicine.

[220]  P. Reaven,et al.  Lovastatin, nicotinic acid, and rhabdomyolysis. , 1988, Annals of internal medicine.

[221]  M. Quiñones,et al.  Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. , 1988, JAMA.

[222]  S. Grundy.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. , 1988, The New England journal of medicine.

[223]  S. Grundy,et al.  Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. , 1988, The New England journal of medicine.

[224]  D. Fleming,et al.  More on rifampin prophylaxis against Haemophilus influenzae b in day-care facilities. , 1988, The New England journal of medicine.

[225]  D. Illingworth,et al.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. , 1988, The New England journal of medicine.

[226]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[227]  Y. Tsujita,et al.  CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species. , 1986, Biochimica et biophysica acta.

[228]  R. Stewart,et al.  A review of medication errors and compliance in ambulant patients , 1972, Clinical pharmacology and therapeutics.

[229]  U. Bergman,et al.  Drug-related problems causing admission to a medical clinic , 2004, European Journal of Clinical Pharmacology.

[230]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[231]  Y. Horsmans.  Differential metabolism of statins: importance in drug-drug interactions , 1999 .

[232]  F. Finkelstein,et al.  Evaluating patients with renal failure for renal artery stenosis with gadolinium-enhanced magnetic resonance angiography. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[233]  P. Neuvonen,et al.  PHARMACOKINETICS AND DISPOSITION , 1999 .

[234]  M. Bottorff,et al.  Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy. , 1999, Clinical therapeutics.

[235]  M J Cupp,et al.  Cytochrome P450: new nomenclature and clinical implications. , 1998, American family physician.

[236]  J. Spence,et al.  Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates) , 1998, Clinical pharmacokinetics.

[237]  K. Goa,et al.  Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. , 1997, PharmacoEconomics.

[238]  H. Choisy,et al.  Pravastatin: interaction with oral anticoagulant? , 1996, BMJ.

[239]  T. Leemann,et al.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.

[240]  A. Gotto,et al.  Antihyperlipidaemic Agents , 1994, Drug safety.

[241]  B. Angelin,et al.  Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. , 1993, The American journal of medicine.

[242]  J. D. Karkas,et al.  Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.

[243]  A. Y. Lu,et al.  Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes. , 1990, Biochemical pharmacology.

[244]  D. E. Duggan,et al.  Physiological disposition of HMG-CoA-reductase inhibitors. , 1990, Drug metabolism reviews.

[245]  D. Illingworth,et al.  Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs. , 1989, Arteriosclerosis.